PCN101 COST-UTILITY ANALYSIS OF DASATINIB AS A SECOND-LINE TREATMENT IN THE CHRONIC PHASE OF CHRONIC MYELOID LEUKAEMIA IN RUSSIA
Nov 1, 2010, 00:00
10.1016/S1098-3015(11)71996-9
https://www.valueinhealthjournal.com/article/S1098-3015(11)71996-9/fulltext
Title :
PCN101 COST-UTILITY ANALYSIS OF DASATINIB AS A SECOND-LINE TREATMENT IN THE CHRONIC PHASE OF CHRONIC MYELOID LEUKAEMIA IN RUSSIA
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)71996-9&doi=10.1016/S1098-3015(11)71996-9
First page :
A270
Section Title :
RESEARCH POSTER ABSTRACTS
Open access? :
No
Section Order :
155